Rna Interference
Novel injectable agent lowers Lp(a) by more than 80% at 36 weeks
CHICAGO — Zerlasiran, a novel injectable small interfering RNA molecule, lowered lipoprotein(a) by more than 80% compared with placebo at 36 weeks, according to the results of the ALPACAR trial.
Vutrisiran reduces mortality, CV events in ATTR amyloidosis with cardiomyopathy
Alnylam Pharmaceuticals announced the positive top-line results of the phase 3 HELIOS-B trial of its investigational RNA interfering therapy vutrisiran for the treatment of transthyretin amyloidosis with cardiomyopathy.
Plozasiran lowers APOC3, triglycerides, other lipids in high-risk populations
In patients with severe hypertriglyceridemia, plozasiran, a novel RNA interference agent, lowered apolipoprotein C-III and triglycerides and improved other lipid parameters, according to the final results of the phase 2b SHASTA-2 trial.
RNA interference silences RAGE with no detrimental effect on lungs in patients with asthma
SAN DIEGO — Study participants tolerated an inhaled therapeutic that silences the expression of a receptor for advanced glycation end-products in the lungs, according to a poster at the American Thoracic Society International Conference.
RNA interference agents appear to benefit patients with mixed hyperlipidemia
In two phase 2b trials, RNA interference agents were associated with reductions in triglycerides compared with placebo for patients with mixed hyperlipidemia.
Phase 2 trial of novel injectable antihypertensive drug meets primary endpoint
Alnylam announced that the KARDIA-2 phase 2 trial of its novel injectable antihypertensive drug zilebesiran met its primary endpoint.
Licensing agreement to advance RNA-targeting meds for neurological conditions
A French biotechnology company has announced a global license agreement with a California-based biotech firm to utilize the former’s platform technology for delivery of RNA-targeted therapeutics.
RNA interference therapies safely lower atherosclerotic cholesterol
PHILADELPHIA — Three phase 2 trials, two of apolipoprotein C-III inhibition and one of angiopoietin-like protein 3 inhibition, demonstrated the efficacy and safety of dyslipidemia treatment via RNA interference.
Topline phase 2 data show potent, dose-dependent BP reduction with zilebesiran
An investigational RNA interference agent targeting angiotensin demonstrated a dose-dependent, clinically significant reduction in 24-hour mean systolic BP in adults with hypertension in a phase 2 trial, according to a press release.
Zilebesiran lowers blood pressure in phase 1 trial
Zilebesiran, a novel RNA interference agent, lowered serum angiotensinogen levels and 24-hour ambulatory blood pressure for 24 weeks, according to the results of a phase 1 trial.